LifeCycle Pharma A/S to Host Conference Call Announcing Annual Report 2008

Investor Service Announcement no. 1/2009
To: NASDAQ OMX Nordic Exchange Copenhagen 	Hørsholm, Denmark, March 2, 2009

LifeCycle Pharma A/S to Host Conference Call Announcing 
Annual Report for 2008

LifeCycle Pharma A/S (OMX: LCP) will announce the Annual Report for 2008 on
Tuesday March 3, 2009. LCP's Executive Management will host an accompanying
conference call to discuss the financial results on Tuesday March 3, 2009 at
17:00 CET (Denmark); 16:00 GMT (London), 11:00 AM ET (New York), 08:00 AM PT
(San Francisco). 

To access the live conference call, please dial one of the following numbers:
+1 866 966 5335 (US)
+44 2030 032 666 (UK)
+45 8088 8649 (DK)

An audio replay of the conference call will be available on www.lcpharma.com
from Tuesday, March 3, 2009 at 20:00 CET (Denmark); 19:00 GMT (London), 02:00
PM ET (New York), 11:00 AM PT (San Francisco), through Friday, April 3, 2009 by
dialing +44 2081 961 998 (UK) or +1 866 583 1035 (US), and entering access code
8403 264#. 

For more information, please contact:
Dr. Jim New 							Peter Schøtt Knudsen
President & Chief Executive Officer 		or		Head of Investor Relations
Phone: + 45 7033 3300 						Phone: + 45 2055 3817
Email: JSN@lcpharma.com 					Email: PSK@lcpharma.com

About LifeCycle Pharma A/S (LCP)
Based in Hørsholm, Denmark, with an office in New York, LCP is an emerging
specialty pharmaceutical company. Clinical development is the core of LCP's
effort to develop a product portfolio which includes products for
immunosuppression, specifically organ transplantation, and products to combat
certain cardiovascular diseases. As a fully integrated company, LCP adapts new
technologies on a fast commercial timetable. LCP's unique, patented delivery
technology, MeltDose®, can improve absorption and bioavailability - at
low-scale up costs - not only for a broad spectrum of drugs already on the
market but also for new chemical entities. LCP has  a cholesterol-lowering
product, Fenoglide™, currently on the U.S. market and a diversified near- and
medium-term pipeline with four product candidates in clinical trials and a
number of projects one in preclinical development. LCP is listed on the NASDAQ
OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For further
information, please visit www.lcpharma.com.